Adintrevimab - Invivyd
Alternative Names: ADG-20Latest Information Update: 28 Mar 2024
At a glance
- Originator Adagio Therapeutics
- Developer Invivyd
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus attachment inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (IV)
- 22 Nov 2022 Invivyd terminates a phase-II/III STAMP trial as the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information in COVID-2019 infections (In adolescents, In children, In adults, In the elderly) in Argentina, Brazil, Bulgaria, Germany, Greece, Hungary, Moldova, Poland, Romania, South Africa and Ukraine (IM) (EudraCT2020-006082-11) (NCT04805671)
- 22 Nov 2022 Invivyd terminates a phase-II/III EVADE trial as the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information in COVID-2019 infections (In adolescents, Prevention, In adults) in USA, Argentina, Bulgaria, Czech Republic, Georgia, Germany, Moldova, Poland, Romania and Ukraine (IM) (NCT04859517)